
Loading, please wait...

Loading, please wait...

Recent molecular studies have established a critical link between HS1BP3 and cancer malignancy, particularly within aggressive gastric and breast carcinomas. The HCLS1-Binding Protein 3 (HS1BP3) interacts directly with the SH3 domain of cortactin. This interaction promotes a malignant phenotype that facilitates tumor progression. Furthermore, clinical data indicate that high HS1BP3 expression correlates with significantly reduced survival for patients with gastric adenocarcinoma and triple-negative breast carcinoma (TNBC). Consequently, identifying these molecular markers could improve prognostic accuracy in clinical settings.
Researchers mapped the interaction site to the third proline-rich region (PRR3.1) of HS1BP3. This specific region is essential for several oncogenic processes. Specifically, the interaction drives cancer cell proliferation and extracellular matrix degradation. Moreover, HS1BP3 regulates the secretion pathways that cancer cells use to invade surrounding tissues. In addition, the study found that HS1BP3 expression levels match the expression of the scaffold protein TKS5. Therefore, the HS1BP3-cortactin axis serves as a master regulator of the invasive machinery in these high-risk cancers.
The study also highlights how mutations in the HS1BP3 PRR3.1 site alter cellular behavior. Specifically, these mutations cause the scaffold protein TKS5 to accumulate within multivesicular endosomes. This buildup suggests a failure in the normal secretion process, which paradoxically supports the aggressive nature of the tumor. Consequently, these findings provide a mechanical explanation for why HS1BP3 levels correlate so strongly with poor patient survival. Since TNBC and gastric cancers often lack targeted treatment options, these insights into endosomal trafficking offer a potential new therapeutic target.
HS1BP3 serves as a biomarker for poor prognosis. High levels of this protein are associated with shorter survival times in gastric adenocarcinoma and triple-negative breast cancer patients due to increased cell invasion.
HS1BP3 binds to the SH3 domain of cortactin via its PRR3.1 region. This interaction is necessary for the cell's ability to degrade the extracellular matrix and proliferate rapidly.
TKS5 is an invadopodia scaffold protein. When HS1BP3 is mutated or dysregulated, TKS5 accumulates in multivesicular endosomes, which disrupts normal secretion and modulates the cancer's malignant phenotype.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Løchen AA et al. Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy. Mol Oncol. 2026 Apr 10. doi: 10.1002/1878-0261.70248. PMID: 41960636.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Research highlights how the HS1BP3-cortactin interaction drives gastric and breast cancer progression, impacting patient survival and cell invasion pathways...
6 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday